Home > Insider Trading > Filing (0001615219-16-000183)

Filing Details

Accession Number:: 0001615219-16-000183
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-01 10:19:59
Reporting Period:: 2016-05-27

Filing Date:: 2016-06-01
Accepted Time:: 2016-06-01 10:19:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1615219	Flex Pharma Inc.	FLKS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291961	H Christoph Westphal	C/O Flex Pharma, Inc. 800 Boylston Street Boston MA 02199	President And Ceo	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-05-27	17,300	$12.68	3,153,861	No	4	P	Indirect	See notes
Common Stock	Acquisiton	2016-05-31	5,000	$12.66	3,158,861	No	4	P	Indirect	See notes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See notes
No	4	P	Indirect	See notes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,925,248	Direct

Footnotes

The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $12.54 to $12.80. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
On May 27, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 17,300 shares of common stock of the Issuer (the "Common Shares"). Following such purchase, Longwood Fund III owned 456,597 Common Shares and Longwood Fund II, L.P. ("Longwood Fund II") owned 2,697,264 Common Shares.
Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $12.41 to $13.00. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
On May 31, 2016, Longwood Fund III purchased 5,000 Common Shares. Following such purchase, Longwood Fund III owned 461,597 Common Shares and Longwood Fund II owned 2,697,264 Common Shares.